Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 276948
Licensor grants to University a worldwide, exclusive solely for use in the Anthracycline Field License, with right to sublicense for value, the subject matter of U.S. Application No.
09/122,427 (MDA94-031 CON) and its foreign equivalents, including the right to manufacture, use, market and/or sell products or services covered by the Subject Patent, and any divisonals, continuations, resissues, reexaminations or extensions thereof.
Licensor shall discontinue, and shall cause its Subsidiaries and sublicensees to discontinue, the manufacture, use, marketing and sale of Products.
Anthracyclines are a class of drugs used in cancer chemotherapy that are extracted from Streptomyces bacterium. These compounds are used to treat many cancers, including leukemias, lymphomas, breast, stomach, uterine, ovarian, bladder cancer, and lung cancers.
Licensor is a biotechnology company developing technologies and product candidates to treat cancers and infectious diseases, primarily based on immunological approaches.
IPSCIO Record ID: 259856
Annamycin is an anthracycline antibiotic being investigated for the treatment of cancer.
Licensor is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. The Licensor's clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.
IPSCIO Record ID: 29382
The Company manufactures its bulk requirements for ixabepilone in its own facilities including the manufacturing of the active ingredient. The drug product which comprises a pharmaceutical kit is finished by Baxter Oncology GmbH.
IPSCIO Record ID: 275835
4-Demethoxy-3-desamino-2-halo-anthracycline and pharmaceutical composition containing same,
3-Amino-2 halo-anthracycline antibiotics ,
1-fluoro, 4-fluoro, and 1,4-difluoro-2-halo anthracycline antibiotics, and,
1-fluoro, 4-fluoro, and 1,4-difluoro anthracycline anticancer antibiotics.